NCT05554367 2026-03-18
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Eli Lilly and Company
AstraZeneca
Dana-Farber Cancer Institute
Incyte Corporation